This study was funded by the maker of Novolog. These two studies aren't entirely congruent: The first one pitted a glargine-plus-oral regimen against 70/30 insulin alone, whereas the second ...
Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback